Question explored with the scientific record
Menbendazole for cancer, yeah or nay?
Mebendazole shows real anti-cancer activity in multiple preclinical models, but the human evidence is thin enough that calling it a cancer treatment is premature.
The evidence here is all preclinical—cell lines, mouse xenografts, and patient-derived spheroids. No human cancer trial results are in the retrieved records. The mechanism is plausible: mebendazole binds β-tubulin and disrupts microtubules [6], the same class of target as the chemotherapy vincristine. But it also hits other pathways. In glioblastoma models, mebendazole extended survival by 17% alone and by 91% when combined with ATAT1 knockdown [1]. In a leukemia xenograft, it pushed median survival from 49 to 76 days [4]. In meningioma spheroids, it prevented invasion in 17 of 19 samples that would have invaded [5]. In CML blast crisis, it disrupted a core regulatory circuit and slowed progression [2].
The evidence is not weak in quality—these are controlled experiments with hard endpoints (survival, invasion). But it is weak in scope. Every study is either in vitro or in a mouse. The one human study in the evidence uses mebendazole for a parasitic worm infection, not cancer [3]. That tells you the drug is tolerated at standard doses, but says nothing about anti-tumor efficacy in a human.
| Model | Intervention | Outcome | Source |
|---|---|---|---|
| GBM mouse | Mebendazole alone | 17% survival increase | [1] |
| GBM mouse | Mebendazole + ATAT1 KD | 91% survival increase | [1] |
| AML xenograft | Mebendazole 50 mg/kg | Median survival 76 vs 49 days | [4] |
| Meningioma spheroids | Mebendazole 1.25–5 µM | Invasion prevented in 17/19 | [5] |
| CML mouse | Mebendazole | Slowed progression | [2] |
My call: mebendazole has a strong mechanistic case and consistent preclinical signal across multiple cancer types, but the gap between a mouse and a human patient is enormous. Without a single human cancer trial in the evidence, the burden of proof has not been met. Confidence: low for human efficacy, moderate for the preclinical rationale.
Sources examined 6
-
Microtubule Acetylation Regulates the Malignant Phenotype of Glioblastoma and is a Promising Therapeutic Target
Targeting ATAT1-driven α-tubulin K40 acetylation suppresses glioblastoma invasion and proliferation, reduces oncogenic signaling and therapy resistance, and enhances sensitivity to microtubule depolymerizers and temozolomide, improving survival in preclinical GBM models.
DOI: 10.64898/2026.06.15.732342 -
The transcriptional regulatory circuit as a driver and therapeutic target in CML blast crisis
The study identifies a four-transcription-factor core regulatory circuit (MEF2C, MYB, MEIS1, ZEB2) driving transcriptional and chromatin remodeling in CML blast crisis, elucidates how this circuit promotes BP progression through GLUL-mediated purine metabolism and Rho GTPase sig…
DOI: 10.1101/2025.11.02.686161 -
Magnetic resonance imaging findings and clinical manifestations in cerebral angiostrongyliasis from Dali, China
Magnetic resonance imaging of 27 Angiostrongylus cantonensis infections in Dali reveals pia mater–predominant eosinophilic meningitis with encephalitis/vasculitis patterns on contrast MRI, aiding diagnosis and guiding albendazole/mebendazole plus corticosteroid therapy.
DOI: 10.1002/brb3.1361 -
Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index
A study that introduces the Lineage Maturation Index (LMI) to quantify differentiation status from gene expression data, uses it to screen for differentiation therapies in AML, and identifies mebendazole as a differentiation-inducing agent that promotes differentiation in leukem…
DOI: 10.1038/s41598-019-53290-3 -
Mebendazole Attenuates Cellular Invasion in a 3D Culture Model of Meningioma by Disrupting Rho-GTPase-Mediated Microtubule Function
Mebendazole reduces invasion of patient-derived meningothelial and atypical meningioma spheroids in a 3D invasion model by disrupting Rho-GTPase–mediated microtubule function, suggesting repurposing potential for grade I/II meningiomas.
DOI: 10.32604/or.2026.074958 -
Modes of action of anthelmintic drugs
A comprehensive review of the cellular and molecular modes of action of major anthelmintic drugs across nematodes and other helminths, detailing nicotinic receptor agonists, GABA and glutamate-gated chloride channels, calcium permeability, microtubule disruption, protonophores, …
DOI: 10.1016/s1090-0233(05)80005-x